Mri scan to predict treatment response in liver cancer
Part of Cancer, Digestive system clinical trials.
This study uses a special MRI technique (3D-MRE) to see if the structure of your liver tumor can predict how well you will respond to conversion therapy, which is treatment designed to shrink the tumor enough for surgery. If your tumor is likely to respond, this could help your doctor choose the best treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have liver cancer (either starting in the liver or spread there) that is not removable by surgery right now.
- Your doctor plans to treat you with 'conversion therapy' — treatment to shrink the tumor so surgery becomes possible.
- Your liver function must be good enough (Child-Pugh class A or B) if you have primary liver cancer.
- You must be fully active or restricted only in physically strenuous activity (score 0-1 on the ECOG scale).
- You must be able to have an MRI scan, and you must not have metal implants or other reasons to avoid MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special MRI scan after liver surgery can help predict if the cancer might come back. By measuring the stiffness of the tissue around the tumor, doctors hope to identify patients who may need closer monitoring.
This study uses a special MRI scan to measure liver stiffness before surgery to remove liver tumors. The goal is to see if this scan can help predict surgical risks and improve outcomes for patients undergoing liver surgery.
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
This trial uses MRI scans to study how colorectal cancer that has spread to the liver grows. It may help doctors choose better treatments.
This trial uses special MRI scans to learn more about liver cancer (hepatocellular carcinoma) before and during treatment with TACE or SIRT. It may help doctors better understand how the tumor responds to therapy.
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
Hear when a new Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.